Skye Bioscience Announces Resignation Of CFO John Sharp Effective September 8; Appoints CEO Punit Dhillon As Principal Financial And Accounting Officer
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001516551/000162828026061558/skye-20260908.htm
Stocks · News reference
8-K/A filing — Skye Bioscience, Inc. (SKYE)
Filed: 2026-08-20 AccNo: 0001628280-26-058120 Size: 147 KB Item 3.03: Material Modifications to Rights of Security Holders
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Skye Bioscience, Inc. (SKYE)
Filed: 2026-09-11 AccNo: 0001628280-26-061558 Size: 154 KB Item 1.02: Termination of a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move
Skye Bioscience shares rise 6% after hours on a $22M equity purchase agreement and warrant issuance.
Skye Bioscience Enters Into Securities Purchase Agreement With Redmile Affiliate For Aggregate Purchase Price Of Up To $22M
Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the "Company"), with the U.S. Securities and Exchange